Related Experiment Video
Updated: Apr 18, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Cardiovascular risk stratification in overweight or obese patients in primary prevention. Implications for use of
Walter Masson1, Martín Lobo1, Melina Huerín1
1Consejo de Epidemiología y Prevención Cardiovascular, Sociedad Argentina de Cardiología, Buenos Aires, Argentina.
Background And Objectives:
Cardiovascular risk estimation in patients with overweight/obesity is not standardized. Our objectives were to stratify cardiovascular risk using different scores, to analyze use of statins, to report the prevalence of carotid atherosclerotic plaque (CAP), and to determine the optimal cut-off point (OCP) of scores that discriminate between subjects with or without CAP.
Material And Methods:
Non-diabetic patients with overweight or obesity in primary prevention were enrolled. The Framingham score (FS), the European score (ES), and the score proposed by the new American guidelines (NS) were calculated, and statin indication was evaluated. Prevalence of CAP was determined by ultrasound examination. A ROC analysis was performed.
Results:
A total of 474 patients (67% with overweight and 33% obese) were enrolled into the study. The FS classified the largest number of subjects as low risk. PAC prevalence was higher in obese as compared to overweight subjects (44.8% vs. 36.1%, P=.04). According to the FS, ES, and NS respectively, 26.7%, 39.1%, and 39.1% of overweight subjects and 28.6%, 39.0%, and 39.0% of obese subjects had an absolute indication for statins. All three scores were shown to acceptably discriminate between subjects with and without CAP (area under the curve>0.7). The OCPs evaluated did not agree with the risk category values.
Conclusions:
Risk stratification and use of statins varied in the overweight/obese population depending on the function used. Understanding of the relationship between scores and presence of CAP may optimize risk estimate.
Related Concept Videos
Atherosclerosis III: Management
Drug Dosing: Obese Patients
Coronary Artery Disease IV: Preventive Measures
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Angina IV: Management

